TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma

Summary

It is a prospective and multi-center clinical research in China to compare the efficacy, safety and related impact factors between TACE alone and TACE combined with synchronous multi-point MWA/RFA for large and huge liver cancer.

Conditions

• Carcinoma, Hepatocellular

Interventions

PROCEDURE

Thermal Ablation

Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.

DRUG

EADM

EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.

DRUG

Ultra-fluid lipiodol

Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .

OTHER

Gelatin sponge articles

Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.

Sponsors & Collaborators

• Xijing Hospital

  collaborator OTHER

• Changhai Hospital

  collaborator OTHER

• Eastern Hepatobiliary Surgery Hospital

  collaborator OTHER

• Shanghai Cancer Hospital, China

  collaborator OTHER

• Shengjing Hospital

  collaborator OTHER

• The Third Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Jilin Provincial Tumor Hospital

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• Jiangsu Cancer Institute & Hospital

  collaborator OTHER

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Sichuan Cancer Hospital and Research Institute

  collaborator OTHER

• Henan Cancer Hospital

  collaborator OTHER_GOV

• Anhui Provincial Hospital

  collaborator OTHER_GOV

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Shandong Tumor Hospital

  collaborator OTHER

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• Chinese PLA General Hospital

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• LanZhou University

  collaborator OTHER

• Sun Yat-sen University

  collaborator OTHER

• Hunan Provincial People's Hospital

  collaborator OTHER

• Affiliated Zhongshan Hospital of Dalian University

  collaborator OTHER

• Shanghai Zhongshan Hospital

  lead OTHER

Principal Investigators

• Jianhua Wang, MD · Shanghai Zhongshan Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-12-31

Primary Completion

2017-12-31

Completion

2018-04-30

Countries

• China

Study Locations